Track Biogen Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Biogen Inc. BIIB Open Biogen Inc. in new tab

177.34 USD
P/E
21.31
EPS
8.80
P/B
1.51
ROE
7.39
Beta
0.15
Target Price
205.90 USD
Biogen Inc. logo

Biogen Inc.

🧾 Earnings Recap – Q3 2025

Biogen reported a robust third quarter in 2025, highlighted by a 67% growth in launch product revenues and strong demand for LEQEMBI and ZURZUVAE, positioning the company favorably within the neurological and autoimmune markets.

  • Launch products drove significant revenue growth, with LEQEMBI sales reaching $121 million.
  • ZURZUVAE experienced a remarkable 150% increase in year-over-year revenue, reshaping perceptions of postpartum depression.
  • Biogen is advancing a strong pipeline, with 10 Phase III programs, including promising candidates for lupus and other autoimmune diseases.
  • The acquisition of Alcyone Therapeutics enhances Biogen's capabilities in delivering innovative therapies via ASO administration.
  • Strong talent acquisition indicates confidence in Biogen's commercial prospects and new product pipeline.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 7, 2026
P/E21.31
EPS8.80
Book Value124.37
Price to Book1.51
Debt/Equity36.47
% Insiders0.165%
Growth
Revenue Growth-0.07%
Earnings Growth0.19%
Estimates
Forward P/E11.56
Forward EPS16.23
Target Mean Price205.90

DCF Valuation

Tweak assumptions to recompute fair value for Biogen Inc. (BIIB)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Biogen Inc. Logo Biogen Inc. Analysis (BIIB)

United States Health Care Official Website Stock

Is Biogen Inc. a good investment? Biogen Inc. (BIIB) is currently trading at 177.34 USD. Market analysts have a consensus price target of 205.90 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 21.31. This valuation is generally in line with the broader market.

Earnings Schedule: Biogen Inc. is expected to release its next earnings report on May 7, 2026. The market consensus estimate for Forward EPS is 16.23.

Investor FAQ

Does Biogen Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Biogen Inc.?

Biogen Inc. is classified as a Stock. You can compare it against 16 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 7, 2026. The company currently has a trailing EPS of 8.80.

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Exchange Ticker
TLO (Poland) BIIB-U.TI
BUE (Argentina) BIIB.BA
SGO (Chile) BIIB.SN
GER (Germany) IDP.DE
MUN (Germany) IDP.MU
MEX (Mexico) BIIB.MX
VIE (Austria) BIIB.VI
SAO (Brazil) BIIB34.SA
BER (Germany) IDP.BE
DUS (Germany) IDP.DU
FRA (Germany) IDP.F
HAN (Germany) IDP.HA
HAM (Germany) IDP.HM
STU (Germany) IDP.SG
NMS (United States) BIIB
LSE (United Kingdom) 0R1B.L

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Jan. 18, 2001 3.000000
Dec. 21, 1999 2.000000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion